Last updated: 11/07/2018 18:20:39
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study To Evaluate The Efficacy Of Oral Naratriptan (2.5mg) For The Treatment Of Migraine In Subjects Who Do Not Respond To Oral Sumatriptan (50mg)
Clinicaltrials.gov ID
Not applicable
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Trial overview
Official title: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study To Evaluate The Efficacy Of Oral Naratriptan (2.5mg) For The Treatment Of Migraine In Subjects Who Do Not Respond To Oral Sumatriptan (50mg)
Trial description: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study To Evaluate The Efficacy Of Oral Naratriptan (2.5mg) For The Treatment Of Migraine In Subjects Who Do Not Respond To Oral Sumatriptan (50mg)
Primary purpose:
Not applicable
Trial design:
Not applicable
Masking:
Not applicable
Allocation:
Not applicable
Primary outcomes:
Not applicable
Secondary outcomes:
Not applicable
Interventions:
Not applicable
Enrollment:
Not applicable
Primary completion date:
Not applicable
Observational study model:
Not applicable
Time perspective:
Not applicable
Clinical publications:
Abstract: Naratriptan is effective for the treatment of migraine headache in sumatriptan non responders. Stark, S MD, O'Quinn, S MD, McNeal, S MD, Pait, G MD, and Watson, C MD American Academy of Neurology 51st Annual Meeting 4/17/1999 Toronto, Canada
Abstract: Naratriptan is effective for the treatment of migraine headache in sumatriptan non responders. Stark, S MD, O'Quinn, S MD, McNeal, S MD, Putnam, G MD, and Watson, C MD 41st Annual Scientific Meeting of the American Association for the Study of Headache 6/11/1999 Boston, MA
Abstract: Naratriptan is effective for the treatment of migraine headache in sumatriptan non-responders. Spierings, E L H, Stark, S, O'Quinn, S, McNeal, S, Pait, G, and Watson, C 9th Congress of the International Headache Society 6/22/1999 Barcelona, Spain
Stark S; Naratriptan efficacy in migraineurs who respond poorly to oral sumatriptan: HEADACHE 2000;40(7)513-520.
Medical condition
Migraine Disorders
Product
naratriptan
Collaborators
Not applicable
Study date(s)
September 1997 to June 1998
Type
Not applicable
Phase
4
Participation criteria
Sex
Not applicable
Age
Not applicable
Accepts healthy volunteers
Not applicable
Inclusion and exclusion criteria
Trial location(s)
This study does not involve prospective enrollment of participants.
Study documents
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Not applicable
Recruitment status
Study complete
Actual primary completion date
Not applicable
Actual study completion date
1998-30-06
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website